Covid-19 vaccine: Bharat Biotech's Covaxin goes off clinical trial mode
Bharat Biotech’s Covaxin on Wednesday got the nod from the subject expert committee (SEC), an independent panel set up by the Drugs Controller General of India (DCGI) to advise it, for a restricted emergency use of the Covid-19 vaccine. Covaxin was granted restricted use approval in ‘clinical trial mode’ in January by the DCGI. At that time, the phase 3 trial on 25,800 volunteers was underway. Read more
RBI takes IDBI Bank out of PCA framework after lender improves finances
Private lender IDBI Bank is out of prompt corrective action